Adjuvant Radiotherapy

Negative/Low Hormone Receptor and APOcrine Lobular Invasive Breast Carcinoma - A Real-World International Cohort Study

De-escalation of RNI in Breast Cancer Patients With pN0 After Neoadjuvant Therapy

Adjuvant Therapy of Skin Melanoma With Alpha Interferon and Naderin

Neoadjuvant SBRT Followed by Nab-Paclitaxel Combined With Toripalimab in HR+/HER2- Breast Cancer

BRIDGE Study: Neoadjuvant Finotonlimab, Cetuximab, and Docetaxel in Resectable Recurrent HNSCC After Immunotherapy Progression

EMERALD: Endocrine Therapy oMission With Radiation in ER+ Breast Cancer: Assessing Quality of Life and Disease Control: a Prospective Phase II Trial

Study of a Strategy Integrating Adjuvant Radiation Therapy Versus Strategy Based on Monitoring in the Treatment of Carcinomas Spinocellular With High Risk of Recurrence

Adjuvant Radiotherapy for Stage II/III Thymoma After Complete Resection

Becotatug Vedotin (MRG003) in Combination With PD-1 Inhibitor Versus PD-1 Inhibitor for the Treatment of EGFR-positive, CPS≥1 Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

Pure Florid and Pleomorphic Lobular Carcinoma in Situ of the Breast: Towards an Increasingly Uniform Management

RW Study of Adjuvant Radiotherapy in Locally Advanced Thyroid Cancer

Low-Dose Radiotherapy and Anti-PD-1 Immunotherapy as Neoadjuvant Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

Prospective, Observational, Real-world Oral Malignant Tumors Study

Phase II Multi-centered Study of Perioperative Ivonescimab Versus Pembrolizumab Combined with Standard of Care (SOC) in Patients with Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma

Effects of Radiotherapy in Borderline and Malignant Phyllodes Tumors After R0 Resection

Adjuvant Radiotherapy for Esophageal Squamous Cell Carcinoma in the Era of Immunotherapy

Neoadjuvant Radiotherapy for Breast Cancer

Association of Adjuvant Radiotherapy of Non-metastatic Breast Carcinoma With Immunomodulation and Circulating Tumor Cell Phenotype in Relation to Patient Age.

Intermediate Risk Cervical Cancer: Radical Surgery +/- Adjuvant Radiotherapy

Comprehensive Bladder Preservation Therapy on Patients With Muscle Invasive Bladder Cancer